In-Silico Structure Database (LMISSD)

Back

LMISSD: Sum Composition Results

Abbreviation Formula Mass Main Class Sub Class
GlcNAcα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 42:2;O2 C76H137N3O28 1539.938869 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 42:2;O2 C76H137N3O28 1539.938869 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 42:2;O2 C76H137N3O28 1539.938869 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 42:1;O2 C76H139N3O28 1541.954519 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 42:1;O2 C76H139N3O28 1541.954519 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 42:1;O2 C76H139N3O28 1541.954519 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 42:1;O2 C76H139N3O28 1541.954519 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C74H134N2O31 1546.897065 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 34:1;O2 C72H130N2O33 1550.855595 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 36:1;O2 C74H134N2O32 1562.891980 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C74H134N2O32 1562.891980 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C74H134N2O32 1562.891980 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 36:1;O2 C74H134N2O32 1562.891980 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 44:2;O2 C78H141N3O28 1567.970169 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 44:2;O2 C78H141N3O28 1567.970169 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 44:2;O2 C78H141N3O28 1567.970169 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 44:2;O2 C78H141N3O28 1567.970169 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 44:1;O2 C78H143N3O28 1569.985819 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 44:1;O2 C78H143N3O28 1569.985819 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 44:1;O2 C78H143N3O28 1569.985819 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 44:1;O2 C78H143N3O28 1569.985819 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C76H138N2O31 1574.928365 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-3GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O32 1575.887229 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O32 1575.887229 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcβ1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O32 1575.887229 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O32 1575.887229 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 36:1;O2 C74H134N2O33 1578.886895 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 38:1;O2 C76H138N2O32 1590.923280 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C76H138N2O32 1590.923280 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 38:1;O2 C76H138N2O32 1590.923280 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 38:1;O2 C76H138N2O32 1590.923280 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcβ1-3Galα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O33 1591.882144 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-4GlcNAcβ1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O33 1591.882144 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O33 1591.882144 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4GlcNAcα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O33 1591.882144 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O33 1591.882144 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O33 1591.882144 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 34:1;O2 C74H133N3O33 1591.882144 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C78H142N2O31 1602.959665 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-3GlcNAcβ1-3Galα1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 36:1;O2 C76H137N3O32 1603.918529 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C76H137N3O32 1603.918529 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcβ1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C76H137N3O32 1603.918529 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C76H137N3O32 1603.918529 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 38:1;O2 C76H138N2O33 1606.918195 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Fucα1-2Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 40:1;O2 C78H142N2O32 1618.954580 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C78H142N2O32 1618.954580 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ-Cer 40:1;O2 C78H142N2O32 1618.954580 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galβ1-4(Fucα1-3)GlcNAcβ1-3Galα1-3Galβ1-4Glcβ-Cer 40:1;O2 C78H142N2O32 1618.954580 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
GalNAcβ1-3Galα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 36:1;O2 C76H137N3O33 1619.913444 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
Galα1-3Galβ1-4GlcNAcβ1-3(GalNAcβ1-4)Galβ1-4Glcβ-Cer 36:1;O2 C76H137N3O33 1619.913444 Neutral glycosphingolipids [SP05] Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]